Immunoproliferative Disorders: Clinical Trials

14,262 trials for Immunoproliferative Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6379 completed, 2036 recruiting, 1742 unknown, 1684 terminated. 6187 Phase 2, 4565 Phase 1, 1356 Not applicable, 1304 Phase 3, 282 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26187Completed 2754, Terminated 872, Recruiting 848, Unknown 640, Active not recruiting 543, Withdrawn 281, Not yet recruiting 214, Suspended 23, Enrolling by invitation 12
Phase 14565Completed 2039, Terminated 728, Recruiting 603, Unknown 451, Active not recruiting 354, Withdrawn 226, Not yet recruiting 131, Suspended 27, Enrolling by invitation 6
Not applicable1356Completed 582, Recruiting 241, Unknown 215, Terminated 103, Not yet recruiting 85, Active not recruiting 69, Withdrawn 43, Enrolling by invitation 10, Suspended 8
Phase 31304Completed 622, Unknown 176, Recruiting 168, Active not recruiting 139, Terminated 121, Not yet recruiting 42, Withdrawn 31, Suspended 3, Enrolling by invitation 2
Early Phase 1282Unknown 71, Recruiting 65, Completed 44, Not yet recruiting 36, Terminated 29, Active not recruiting 18, Withdrawn 13, Suspended 6
Phase 4273Completed 124, Unknown 65, Recruiting 32, Terminated 17, Not yet recruiting 13, Active not recruiting 11, Withdrawn 10, Enrolling by invitation 1

Follow Immunoproliferative Disorders: new trials by email Literature Review of Immunoproliferative Disorders trials Research Report on Immunoproliferative Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-11-16
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 2Not yet recruitingExcyte Biopharma Ltd642027-12-012026-11-06
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Individual Exercise, Group Exercise - Multiple Myeloma
Not applicableSuspendedMedical University of Vienna452027-09-012026-10-09
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2Not yet recruitingCity of Hope Medical Center442027-08-042026-09-10
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Astragalus, Placebo - High-grade Lymphoma
Phase 3Not yet recruitingBnai Zion Medical Center602027-08-012026-09-30
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1RecruitingNational Cancer Institute (NCI)152027-07-052026-11-05
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain
VR-PAT - Acute Pain, Pediatric ALL
Not applicableNot yet recruitingNationwide Children's Hospital42027-07-012026-09-09
CAR-T Immunotherapy Targeting CD19- ALL
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-07-012026-11-02
Universal 4SCAR7U Targeting CD7-positive Malignancies
Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Engineered Dendritic Cell Vaccines for Multiple Myeloma
DC vaccines - Multiple Myeloma or Plasmacytoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-302026-11-02
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma
Phase 1WithdrawnFred Hutchinson Cancer Center2027-06-012026-09-11
Multi-CAR-T Cells Targeting B Cell Lymphomas
4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute112027-06-012026-11-02
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 2RecruitingNational Cancer Institute (NCI)802027-05-222026-11-04
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Phase 1Not yet recruitingCity of Hope Medical Center142027-05-162026-11-09
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL
Phase 2Not yet recruitingAbelZeta Inc.552027-05-012026-10-15

Showing 20 of 14262. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3675)  ·  Lymphoma (3020)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2524)  ·  Lymphoma, Non-Hodgkin (2288)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2019)  ·  Lymphoma, Follicular (1876)  ·  Lymphoma, Large B-Cell, Diffuse (1833)  ·  Leukemia (1380)  ·  Hodgkin Disease (1302)  ·  Lymphoma, Mantle-Cell (1212)  ·  Recurrence (1158)  ·  Leukemia, Myeloid, Acute (1033)  ·  Burkitt Lymphoma (977)  ·  Lymphoma, B-Cell, Marginal Zone (865)  ·  Lymphoma, B-Cell (780)

Broader conditions

Immune System Diseases (14193)  ·  Hemic and Lymphatic Diseases (14111)  ·  Neoplasms by Histologic Type (13989)  ·  Lymphoproliferative Disorders (13948)  ·  Neoplasms (13387)  ·  Lymphatic Diseases (11155)  ·  Hematologic Diseases (8255)  ·  Lymphoma (5273)  ·  Leukemia, Lymphoid (4257)  ·  Paraproteinemias (4214)  ·  Cardiovascular Diseases (4153)  ·  Blood Protein Disorders (4140)  ·  Vascular Diseases (4096)  ·  Hemorrhagic Disorders (4066)

Interventions

Cyclophosphamide (1580)  ·  Rituximab (1442)  ·  Dexamethasone (1275)  ·  Lenalidomide (822)  ·  Vincristine (697)  ·  Bortezomib (670)  ·  Doxorubicin (637)  ·  Prednisone (583)  ·  fludarabine (559)  ·  Etoposide (546)  ·  Cytarabine (516)  ·  Melphalan (461)  ·  Methotrexate (456)  ·  fludarabine phosphate (435)  ·  Filgrastim (418)

Sponsors

National Cancer Institute (NCI) (622)  ·  M.D. Anderson Cancer Center (457)  ·  Memorial Sloan Kettering Cancer Center (272)  ·  Fred Hutchinson Cancer Center (177)  ·  Mayo Clinic (161)  ·  Celgene (159)  ·  City of Hope Medical Center (159)  ·  Novartis Pharmaceuticals (141)  ·  Dana-Farber Cancer Institute (139)  ·  Hoffmann-La Roche (138)  ·  Institute of Hematology & Blood Diseases Hospital, China (129)  ·  Children's Oncology Group (113)  ·  St. Jude Children's Research Hospital (113)  ·  Janssen Research & Development, LLC (110)  ·  GlaxoSmithKline (100)

Countries

United States (7612)  ·  China (2018)  ·  France (1387)  ·  Italy (1150)  ·  Germany (987)  ·  Spain (979)  ·  Canada (946)  ·  United Kingdom (945)  ·  Australia (741)  ·  South Korea (556)  ·  Belgium (532)  ·  Poland (474)  ·  Netherlands (451)  ·  Japan (424)  ·  Israel (401)

Results publications

PMID 34515338, PMID 41671463, PMID 35622074, PMID 40135712, PMID 32632956, PMID 32499241, PMID 34398557, PMID 31401903, PMID 40550489, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 26373676, PMID 31221778, PMID 37022569, PMID 37192741, PMID 37505794, PMID 38620092, PMID 22689675, PMID 23524640, PMID 27209293, PMID 27282998, PMID 31050355, PMID 33242441, PMID 39121442, PMID 40802906, PMID 23065508, PMID 23834234, PMID 29358183, PMID 30125215, PMID 31196847, PMID 32816215, PMID 33218965, PMID 34048072, PMID 35285981, PMID 35787017, PMID 40396505, PMID 40501401, PMID 41429239, PMID 18596230, PMID 19238148, PMID 26182309, PMID 28054442, PMID 28751558, PMID 28803351, PMID 30957581, PMID 31023700, PMID 32770353, PMID 33288485

NIH funding

2023 (166), P30CA033572 (109), P30CA015704 (88), 2017 (76), P30CA015083 (76), 2015 (75), 2016 (72), 2018 (69), 2014 (64), U10CA032102 (62), 2019 (57), 2025 (55), U10CA180820 (55), 2009 (51), P30CA016672 (44)